[Corrigendum] Inhibition of RANKL‑induced osteoclastogenesis through the suppression of the ERK signaling pathway by astragaloside IV and attenuation of titanium‑particle‑induced osteolysis

Li,Mingjun; Wang,Wengang; Geng,Li; Qin,Yanru; Dong,Wenjie; Zhang,Xudong; Qin,An; Zhang,Mingzhi

doi:10.3892/ijmm.2018.3617

July-2018 Volume 42 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-2018 Volume 42 Issue 1

Full Size Image

Correction Open Access

[Corrigendum] Inhibition of RANKL‑induced osteoclastogenesis through the suppression of the ERK signaling pathway by astragaloside IV and attenuation of titanium‑particle‑induced osteolysis

Authors:
- Mingjun Li
- Wengang Wang
- Li Geng
- Yanru Qin
- Wenjie Dong
- Xudong Zhang
- An Qin
- Mingzhi Zhang
View Affiliations / Copyright

Affiliations: Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Department of Orthopedics, Shanghai Key Laboratory of Orthopedic Implant, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China

Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
Pages: 685-685
|
Published online on: April 3, 2018

https://doi.org/10.3892/ijmm.2018.3617
Expand metrics +

Article

Mingjun Li, Wengang Wang, Li Geng, Yanru Qin, Wenjie Dong, Xudong Zhang, An Qin and Mingzhi Zhang

Int J Mol Med 36:[Related article:] 1335–1344, 2015;

Following the publication of the article, the authors noticed an error in the published version of Fig. 3. In brief, certain of the images were misplaced, errors which occurred during the preparation and assembly of the figure owing to oversights in labeling of the image data. The corrected version of Fig. 3 is included below.

Figure 3

AS-IV inhibits RANKL-induced osteoclastogenesis. (A) BMMs were treated with different concentrations of AS-IV followed by 30 ng/ml M-CSF and 50 ng/ml RANKL for 5-7 days. Cells were sub- sequently fixed with 4% paraformaldehyde and stained for TRAP. (B) The number of TRAP-positive cells. (C) The area occupied by TRAP-positive cells. (D) BMMs were treated with or without 100 μM AS-IV, followed by 30 ng/ml M-CSF and 50 ng/ml RANKL. Cells were subsequently fixed and stained for TRAP on days 3, 5 and 7. (E) The number of TRAP-positive cells at the indicated time-points. (F) The area occupied by TRAP-positive cells at the indicated time-points. **P<0.01, compared to 0 μM treatment (control). AS-IV, astragaloside IV; RANKL, receptor activator of the nuclear factor-κB ligand; BMMs, bone marrow macrophages; M-CSF, macrophage colony-stimulating factor; TRAP, tartrate-resistant acid phosphatase.

The authors regret that this error occurred, and apologize for the inconvenience caused by the error. They thank the Editor for allowing them the opportunity to publish this Corrigendum.